A biotech developing small molecule therapies that degrade protein aggregates linked to neurodegenerative diseases.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Seed TRIMTECH Therapeutics raised an additional 12 million euros in seed funding, bringing its round to a total of 41 million euros, to advance its protein degrader platforms. | $14M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.